Highly Active Antiretroviral Therapy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research

Viruses, Vol. 15, Pages 2226: Investigating the Role of Anti-TPO Antibodies in HIV-Associated Thrombocytopenia before and after Initiation of HAART: A Case-Control Longitudinal Study
Akinosoglou This longitudinal, case-control study aimed to investigate the role of thrombopoietin (TPO) and anti-TPO antibodies in HIV-associated thrombocytopenia, focusing on the changes seen before and after the initiation of highly active antiretroviral therapy (HAART). Patients were assessed before and at least six months after the initiation of HAART. In total, 75 PLWHIV (age/sex-matched and randomized at 2:1, according to thrombocytopenia status) were included in this study. The baseline assessment revealed significantly higher TPO levels in thrombocytopenic patients (140.45 vs. 106.8 mg/mL, p = 0.008). Furthermo...
Source: Viruses - November 8, 2023 Category: Virology Authors: Aristotelis Tsiakalos John G. Routsias Georgios Schinas Sarah Georgiadou Nikolaos V. Sipsas Karolina Akinosoglou Tags: Article Source Type: research

Viruses, Vol. 15, Pages 2187: Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India & mdash;An Ambi-Directional Cohort Study
Conclusions: Full vaccination with Covishield and Covaxin was effective against COVID-19 infection among PLHIV on treatment; albeit, that of Covaxin was higher. A gap of 4 to 6 weeks between the two doses of COVID-19 vaccine was found to have higher VE among PLHIV. (Source: Viruses)
Source: Viruses - October 30, 2023 Category: Virology Authors: Joe Thomas Priyanka Rajmohan Ponnu Jose Radhika Kannan Rosmi Jose Unnikrishnan Uttumadathil Gopinathan Lucy Raphael Nithya M. Baiju Swathi Krishna Teny Attokaran Jubina Bency A. T Aiswarya Venugopal Soorya Sheela Akhila Kallempadam Lee Jose Susheela J. In Tags: Article Source Type: research

Ocular manifestations of HIV infection at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
CONCLUSION: With the advent of HAART, ocular manifestations of HIV are changing and the incidence of severe ocular opportunistic infections and HIV retinopathy has decreased precipitously. Although this study has shown that patients with a CD4 count <200 cells/μL are at increased risk of developing anterior ocular manifestations of HIV, including cataracts, these diseases are relatively innocuous or easily treatable. Routine ocular screening of HIV patients seems to be substantially less important now than it was in the pre-HAART era.PMID:37881908 | DOI:10.7196/SAMJ.2023.v113i10.950 (Source: South African Medical Journal)
Source: South African Medical Journal - October 26, 2023 Category: African Health Authors: I Ismail M Venter S Ismail N Ally Source Type: research